# NKTR — REZOLVE‑AD 36‑Week Maintenance Update (52‑Week Trial): What the Filing Actually Says, and What It Means for “Durability” ## Executive takeaway Nektar’s Feb. 10, 2026 8‑K discloses that **rezpegaldesleukin (REZPEG/NKTR‑358) showed sustained and in some cases deepening responses through Week 52** in the Phase 2b REZOLVE‑AD study, with **no new safety concerns** in the 36‑week blinded maintenance/escape periods. ["results from the 36-week blinded maintenance period"](0001193125-26-043755|0) ["no new safety concerns identified"](0001193125-26-043755|0) From a biotech watchlist perspective, **this is a meaningful de‑risking of “maintenance durability” inside an on‑treatment design**, but the *bigger* durability debate (remission/off‑drug) is still a future catalyst (company slide deck points to **off‑treatment data in Q1 2027**). ["1-Year Follow-up (Off Treatment) Data Q1 2027"](0001193125-26-043755|2) --- ## 1) What happened (source: SEC disclosure, not social/retail feeds) On **Feb. 10, 2026**, Nektar filed an **8‑K** stating it issued a press release reporting results from the **“36‑week blinded maintenance period”** of its **52‑week REZOLVE‑AD** study of rezpegaldesleukin in **moderate‑to‑severe atopic dermatitis**. ["issued a press release reporting results"](0001193125-26-043755|0) ["36-week blinded maintenance period"](0001193125-26-043755|0) The filing also furnishes (i) the press release (Ex. 99.1) and (ii) a presentation (Ex. 99.2). ["Exhibit 99.1"](0001193125-26-043755|0) ["Exhibit 99.2"](0001193125-26-043755|0) *Note:* Your prompt mentions pre‑market % move and Stocktwits sentiment; those are **not** part of SEC filings/disclosures, so I’m not treating them as evidence here. --- ## 2) Trial design mechanics: why “maintenance durability” is not the same as “off‑drug durability” **REZOLVE‑AD Phase 2b enrolled 393 patients** with moderate‑to‑severe AD. ["enrolled 393 patients"](0001193125-26-043755|0) Structure (as described in the 8‑K / Ex. 99.1): - **16‑week induction**: randomized across **three rezpegaldesleukin dose arms vs placebo**. ["16-week induction period"](0001193125-26-043755|0) - To enter maintenance, rezpegaldesleukin‑treated patients needed **EASI ≥50% improvement (EASI‑50)** at Week 16 and were **re‑randomized 1:1** to continue the same induction dose **monthly (Q4W) or quarterly (Q12W)** through Week 52, blinded. ["achieved ... at least 50"](0001193125-26-043755|0) ["re-randomized (1:1)"](0001193125-26-043755|0) ["monthly (“Q4W”) or quarterly (“Q12W”) through week 52"](0001193125-26-043755|0) - Non‑responders could enter an **escape arm**. ["treatment escape arm"](0001193125-26-043755|0) **Key implication:** the Week 52 “durability” being highlighted here is **durability on extended therapy with reduced frequency**, not yet “remittive effect” off treatment. --- ## 3) What the maintenance data say (Week 52): efficacy + deepening responses ### 3.1 Maintenance of response at Week 52 (selected endpoints) The press release provides a Week 52 table for “Maintenance of Response Among Re‑Randomized Patients Achieving EASI‑50 in 16‑Week Induction” for multiple endpoints (EASI‑75, EASI‑90, vIGA‑AD 0/1, itch NRS). ["Maintenance of Response"](0001193125-26-043755|1) Below are the *exact figures* disclosed in Ex. 99.1 for the **24 µg/kg pooled** maintenance groups: | Endpoint (Week 52) | 24 µg/kg Q4W (pooled) | 24 µg/kg Q12W (pooled) | |---|---:|---:| | Patients (N) | N=55 ["N=55"](0001193125-26-043755|1) | N=56 ["N=56"](0001193125-26-043755|1) | | **EASI‑75** maintained | 71% ["EASI-75 71%"](0001193125-26-043755|1) | 83% ["EASI-75 83%"](0001193125-26-043755|1) | | **vIGA‑AD 0/1** maintained | 85% ["vIGA-AD 0/1 85%"](0001193125-26-043755|1) | 63% ["vIGA-AD 0/1 63%"](0001193125-26-043755|1) | **How to read this:** The filing supports that **meaningful proportions of induction responders maintained stringent endpoints through Week 52** even at **quarterly dosing** (Q12W) in this blinded maintenance design. ["sustained disease control"](0001193125-26-043755|0) ### 3.2 “Deepening” of response: EASI‑100 conversions highlighted The company emphasizes an increase in complete clearance (EASI‑100) during maintenance for 24 µg/kg regimens, including the all re‑randomized population and subsets that already had EASI‑75 or vIGA‑AD response at maintenance baseline. ["increase in percentage of patients who achieved EASI-100"](0001193125-26-043755|0) Key disclosed figures: - Among **all re‑randomized** patients from Week 16→52: - Q4W increased **EASI‑100 from 4% to 22%**. ["increased EASI-100 response from 4% to 22%"](0001193125-26-043755|0) - Q12W increased **EASI‑100 from 9% to 18%**. ["increased EASI-100 response from 9% to 18%"](0001193125-26-043755|0) - Among re‑randomized patients who had **EASI‑75 or vIGA‑AD response at maintenance baseline**: - Q4W increased **EASI‑100 from 6% to 30%**. ["increased EASI-100 response from 6% to 30%"](0001193125-26-043755|0) - Q12W increased **EASI‑100 from 14% to 27%**. ["increased EASI-100 response from 14% to 27%"](0001193125-26-043755|0) **Why this matters for a watchlist:** “deepening” (not just maintenance) can be strategically important in chronic inflammatory diseases—if reproducible, it supports a **maintenance regimen story** (lower frequency after induction) rather than only a short‑term induction effect. The company explicitly frames Q4W/Q12W as enabling “less frequent dosing.” ["less frequent dosing"](0001193125-26-043755|0) --- ## 4) Safety and tolerability: what’s actually disclosed Nektar states the **maintenance safety profile was consistent with induction**, with **no new safety concerns** identified during maintenance and escape. ["consistent with observations from the induction"](0001193125-26-043755|0) ["no new safety concerns identified"](0001193125-26-043755|0) Disclosed quantitative points: - **Discontinuation due to adverse events:** 3.5% (all aggregated patients). ["discontinuation rate due to adverse events was 3.5%"](0001193125-26-043755|0) - **TEAEs:** 72% (re‑randomized REZPEG), 65% (placebo maintenance), 83% (escape). ["Overall rates of treatment-emergent adverse events (TEAEs) were 72%"](0001193125-26-043755|0) ["65% for placebo patients"](0001193125-26-043755|0) ["83% for all escape patients"](0001193125-26-043755|0) - **Most frequent TEAE:** injection site reactions; “nearly all” mild (77%); discontinuations due to ISR 0.7%. ["most frequent TEAE was injection site reactions"](0001193125-26-043755|0) ["nearly all of which were mild (77%)"](0001193125-26-043755|0) ["discontinuation rate due to injection site reactions was 0.7%"](0001193125-26-043755|0) **Interpretation:** For many AD assets, safety/tolerability and chronic dosing feasibility are as important as Week‑16 efficacy. The filing supports that long(‑er) exposure didn’t surface new signals *within this dataset*, though Phase 3 scale and broader populations remain the real test. --- ## 5) Regulatory / development path: what the company says they are doing next The 8‑K states Nektar held an **End of Phase 2 meeting with FDA** and aligned on evaluating a **24 µg/kg Q2W induction regimen for 24 weeks** with **co‑primary endpoints of EASI‑75 and an IGA‑related endpoint** for **two planned Phase 3 registrational trials**. ["End of Phase 2 meeting"](0001193125-26-043755|0) ["24 µg/kg Q2W"](0001193125-26-043755|0) ["24-week induction period"](0001193125-26-043755|0) ["co-primary endpoints of EASI-75"](0001193125-26-043755|0) ["two planned Phase 3 registrational trials"](0001193125-26-043755|0) The Phase 3 trials are described as including a **maintenance period** evaluating **24 µg/kg Q4W and Q12W** maintenance regimens, and the company says it **plans to start Phase 3 in Q2 2026**. ["Phase 3 trials will also include a 36-week maintenance period"](0001193125-26-043755|0) ["evaluate 24 µg/kg Q4W"](0001193125-26-043755|0) ["24 µg/kg Q12W"](0001193125-26-043755|0) ["plans to start the Phase 3 trials in the second quarter of 2026"](0001193125-26-043755|0) The furnished Ex. 99.1 also includes an internal target of **submitting a BLA in 2029** (management quote). ["goal of submitting a BLA in 2029"](0001193125-26-043755|1) **Watchlist implication:** this update is meaningful, but the equity’s *next major* biotech‑style re‑rating typically hinges on (i) Phase 3 start/execution, (ii) Phase 3 topline efficacy/safety, and (iii) financing risk into that path. --- ## 6) Financing and “can they fund it?” (using 10‑Q as baseline disclosure) In its Q3 2025 10‑Q, Nektar reported **~$270.2 million in cash and investments** as of Sept. 30, 2025 and stated it believes it has **sufficient cash/investments to fund operations through at least the next 12 months** from the filing date. ["approximately $270.2 million in cash and investments"](0001193125-25-270230|0) ["sufficient cash and investments ... through at least the next twelve months"](0001193125-25-270230|0) The same 10‑Q discloses the company raised capital via: - **July 2, 2025 underwritten public offering** net proceeds ~**$107.2 million**. ["net proceeds ... approximately $107.2 million"](0001193125-25-270230|0) - **ATM issuance** with net proceeds (Sept/Oct 2025 combined) **$72.5 million**. ["net proceeds of $72.5 million"](0001193125-25-270230|0) **Interpretation:** The filing record supports that they entered 2026 with a recently strengthened balance sheet (as of the last 10‑Q) and explicit runway guidance (≥12 months). That helps, but Phase 3 AD (two registrational trials) is typically expensive—so I would still treat **future dilution/partnering** as a central watchlist risk item. (This is consistent with their own risk disclosures about capital requirements.) ["substantial future capital requirements"](0000950170-25-039389|0) --- ## 7) So—does the 36‑week “durability” move NKTR up a biotech watchlist? ### My watchlist call (filings‑grounded) **Yes—move it up, but “to the top of the monitoring stack,” not straight to a conviction core holding,** because the filing meaningfully strengthens the *case that the drug can maintain and even deepen responses with less frequent dosing* through 52 weeks, and management is positioning this as a bridge to Phase 3. ["sustained disease control"](0001193125-26-043755|0) ["meaningful proportion of patients achieved new"](0001193125-26-043755|0) ["supports advancement to pivotal Phase 3 program"](0001193125-26-043755|1) ### Why I’m not calling it “full durability de‑risked” yet Because “durability” in biotech often means **off‑treatment durability/remission**, and the company’s own deck shows that the **off‑treatment follow‑up** readout is a later event (Q1 2027). ["1-Year Follow-up (Off Treatment) Data Q1 2027"](0001193125-26-043755|2) --- ## 8) Practical watchlist checklist: what I’d want to see next (all tied to disclosed roadmap) 1) **Phase 3 initiation in Q2 2026** (confirm start, sites/enrollment pace, design specifics). ["plans to start the Phase 3 trials in the second quarter of 2026"](0001193125-26-043755|0) 2) Confirmation that the **co‑primary endpoints (EASI‑75 + IGA‑related endpoint)** and the proposed maintenance regimens remain intact as trials launch. ["co-primary endpoints of EASI-75"](0001193125-26-043755|0) ["IGA-related endpoint"](0001193125-26-043755|0) 3) Any updated disclosure on **target population** (bio‑naïve vs bio‑experienced mix) because that can affect response rates and commercial positioning. ["expected to include patients who have not received prior biologics"](0001193125-26-043755|0) 4) Financing commentary as Phase 3 ramps (the company discloses capital dependence risk and lack of committed capital). ["We have no credit facility"](0001193125-25-270230|0) ["substantial future capital requirements"](0000950170-25-039389|0) --- If you want, I can also extract (and cite) the **exact “Risk Factors” language** from the 2024 10‑K that is most relevant to rezpegaldesleukin concentration risk, Phase 3 failure risk, and funding/dilution risk—and then map those directly to the Phase 3 AD plan described in the Feb. 10, 2026 8‑K. ["we are highly dependent on the success of rezpegaldesleukin"](0000950170-25-039389|0)

# NKTR — REZOLVE‑AD 36‑Week Maintenance Update (52‑Week Trial): What the Filing Actually Says, and What It Means for “Durability” ## Executive takeaway Nektar’s Feb. 10, 2026 8‑K discloses that **rezpegaldesleukin (REZPEG/NKTR‑358) showed sustained and in some cases deepening responses through Week 52** in the Phase 2b REZOLVE‑AD study, with **no new safety concerns** in the 36‑week blinded maintenance/escape periods. ["results from the 36-week blinded maintenance period"](0001193125-26-043755|0) ["no new safety concerns identified"](0001193125-26-043755|0) From a biotech watchlist perspective, **this is a meaningful de‑risking of “maintenance durability” inside an on‑treatment design**, but the *bigger* durability debate (remission/off‑drug) is still a future catalyst (company slide deck points to **off‑treatment data in Q1 2027**). ["1-Year Follow-up (Off Treatment) Data Q1 2027"](0001193125-26-043755|2) --- ## 1) What happened (source: SEC disclosure, not social/retail feeds) On **Feb. 10, 2026**, Nektar filed an **8‑K** stating it issued a press release reporting results from the **“36‑week blinded maintenance period”** of its **52‑week REZOLVE‑AD** study of rezpegaldesleukin in **moderate‑to‑severe atopic dermatitis**. ["issued a press release reporting results"](0001193125-26-043755|0) ["36-week blinded maintenance period"](0001193125-26-043755|0) The filing also furnishes (i) the press release (Ex. 99.1) and (ii) a presentation (Ex. 99.2). ["Exhibit 99.1"](0001193125-26-043755|0) ["Exhibit 99.2"](0001193125-26-043755|0) *Note:* Your prompt mentions pre‑market % move and Stocktwits sentiment; those are **not** part of SEC filings/disclosures, so I’m not treating them as evidence here. --- ## 2) Trial design mechanics: why “maintenance durability” is not the same as “off‑drug durability” **REZOLVE‑AD Phase 2b enrolled 393 patients** with moderate‑to‑severe AD. ["enrolled 393 patients"](0001193125-26-043755|0) Structure (as described in the 8‑K / Ex. 99.1): - **16‑week induction**: randomized across **three rezpegaldesleukin dose arms vs placebo**. ["16-week induction period"](0001193125-26-043755|0) - To enter maintenance, rezpegaldesleukin‑treated patients needed **EASI ≥50% improvement (EASI‑50)** at Week 16 and were **re‑randomized 1:1** to continue the same induction dose **monthly (Q4W) or quarterly (Q12W)** through Week 52, blinded. ["achieved ... at least 50"](0001193125-26-043755|0) ["re-randomized (1:1)"](0001193125-26-043755|0) ["monthly (“Q4W”) or quarterly (“Q12W”) through week 52"](0001193125-26-043755|0) - Non‑responders could enter an **escape arm**. ["treatment escape arm"](0001193125-26-043755|0) **Key implication:** the Week 52 “durability” being highlighted here is **durability on extended therapy with reduced frequency**, not yet “remittive effect” off treatment. --- ## 3) What the maintenance data say (Week 52): efficacy + deepening responses ### 3.1 Maintenance of response at Week 52 (selected endpoints) The press release provides a Week 52 table for “Maintenance of Response Among Re‑Randomized Patients Achieving EASI‑50 in 16‑Week Induction” for multiple endpoints (EASI‑75, EASI‑90, vIGA‑AD 0/1, itch NRS). ["Maintenance of Response"](0001193125-26-043755|1) Below are the *exact figures* disclosed in Ex. 99.1 for the **24 µg/kg pooled** maintenance groups: | Endpoint (Week 52) | 24 µg/kg Q4W (pooled) | 24 µg/kg Q12W (pooled) | |---|---:|---:| | Patients (N) | N=55 ["N=55"](0001193125-26-043755|1) | N=56 ["N=56"](0001193125-26-043755|1) | | **EASI‑75** maintained | 71% ["EASI-75 71%"](0001193125-26-043755|1) | 83% ["EASI-75 83%"](0001193125-26-043755|1) | | **vIGA‑AD 0/1** maintained | 85% ["vIGA-AD 0/1 85%"](0001193125-26-043755|1) | 63% ["vIGA-AD 0/1 63%"](0001193125-26-043755|1) | **How to read this:** The filing supports that **meaningful proportions of induction responders maintained stringent endpoints through Week 52** even at **quarterly dosing** (Q12W) in this blinded maintenance design. ["sustained disease control"](0001193125-26-043755|0) ### 3.2 “Deepening” of response: EASI‑100 conversions highlighted The company emphasizes an increase in complete clearance (EASI‑100) during maintenance for 24 µg/kg regimens, including the all re‑randomized population and subsets that already had EASI‑75 or vIGA‑AD response at maintenance baseline. ["increase in percentage of patients who achieved EASI-100"](0001193125-26-043755|0) Key disclosed figures: - Among **all re‑randomized** patients from Week 16→52: - Q4W increased **EASI‑100 from 4% to 22%**. ["increased EASI-100 response from 4% to 22%"](0001193125-26-043755|0) - Q12W increased **EASI‑100 from 9% to 18%**. ["increased EASI-100 response from 9% to 18%"](0001193125-26-043755|0) - Among re‑randomized patients who had **EASI‑75 or vIGA‑AD response at maintenance baseline**: - Q4W increased **EASI‑100 from 6% to 30%**. ["increased EASI-100 response from 6% to 30%"](0001193125-26-043755|0) - Q12W increased **EASI‑100 from 14% to 27%**. ["increased EASI-100 response from 14% to 27%"](0001193125-26-043755|0) **Why this matters for a watchlist:** “deepening” (not just maintenance) can be strategically important in chronic inflammatory diseases—if reproducible, it supports a **maintenance regimen story** (lower frequency after induction) rather than only a short‑term induction effect. The company explicitly frames Q4W/Q12W as enabling “less frequent dosing.” ["less frequent dosing"](0001193125-26-043755|0) --- ## 4) Safety and tolerability: what’s actually disclosed Nektar states the **maintenance safety profile was consistent with induction**, with **no new safety concerns** identified during maintenance and escape. ["consistent with observations from the induction"](0001193125-26-043755|0) ["no new safety concerns identified"](0001193125-26-043755|0) Disclosed quantitative points: - **Discontinuation due to adverse events:** 3.5% (all aggregated patients). ["discontinuation rate due to adverse events was 3.5%"](0001193125-26-043755|0) - **TEAEs:** 72% (re‑randomized REZPEG), 65% (placebo maintenance), 83% (escape). ["Overall rates of treatment-emergent adverse events (TEAEs) were 72%"](0001193125-26-043755|0) ["65% for placebo patients"](0001193125-26-043755|0) ["83% for all escape patients"](0001193125-26-043755|0) - **Most frequent TEAE:** injection site reactions; “nearly all” mild (77%); discontinuations due to ISR 0.7%. ["most frequent TEAE was injection site reactions"](0001193125-26-043755|0) ["nearly all of which were mild (77%)"](0001193125-26-043755|0) ["discontinuation rate due to injection site reactions was 0.7%"](0001193125-26-043755|0) **Interpretation:** For many AD assets, safety/tolerability and chronic dosing feasibility are as important as Week‑16 efficacy. The filing supports that long(‑er) exposure didn’t surface new signals *within this dataset*, though Phase 3 scale and broader populations remain the real test. --- ## 5) Regulatory / development path: what the company says they are doing next The 8‑K states Nektar held an **End of Phase 2 meeting with FDA** and aligned on evaluating a **24 µg/kg Q2W induction regimen for 24 weeks** with **co‑primary endpoints of EASI‑75 and an IGA‑related endpoint** for **two planned Phase 3 registrational trials**. ["End of Phase 2 meeting"](0001193125-26-043755|0) ["24 µg/kg Q2W"](0001193125-26-043755|0) ["24-week induction period"](0001193125-26-043755|0) ["co-primary endpoints of EASI-75"](0001193125-26-043755|0) ["two planned Phase 3 registrational trials"](0001193125-26-043755|0) The Phase 3 trials are described as including a **maintenance period** evaluating **24 µg/kg Q4W and Q12W** maintenance regimens, and the company says it **plans to start Phase 3 in Q2 2026**. ["Phase 3 trials will also include a 36-week maintenance period"](0001193125-26-043755|0) ["evaluate 24 µg/kg Q4W"](0001193125-26-043755|0) ["24 µg/kg Q12W"](0001193125-26-043755|0) ["plans to start the Phase 3 trials in the second quarter of 2026"](0001193125-26-043755|0) The furnished Ex. 99.1 also includes an internal target of **submitting a BLA in 2029** (management quote). ["goal of submitting a BLA in 2029"](0001193125-26-043755|1) **Watchlist implication:** this update is meaningful, but the equity’s *next major* biotech‑style re‑rating typically hinges on (i) Phase 3 start/execution, (ii) Phase 3 topline efficacy/safety, and (iii) financing risk into that path. --- ## 6) Financing and “can they fund it?” (using 10‑Q as baseline disclosure) In its Q3 2025 10‑Q, Nektar reported **~$270.2 million in cash and investments** as of Sept. 30, 2025 and stated it believes it has **sufficient cash/investments to fund operations through at least the next 12 months** from the filing date. ["approximately $270.2 million in cash and investments"](0001193125-25-270230|0) ["sufficient cash and investments ... through at least the next twelve months"](0001193125-25-270230|0) The same 10‑Q discloses the company raised capital via: - **July 2, 2025 underwritten public offering** net proceeds ~**$107.2 million**. ["net proceeds ... approximately $107.2 million"](0001193125-25-270230|0) - **ATM issuance** with net proceeds (Sept/Oct 2025 combined) **$72.5 million**. ["net proceeds of $72.5 million"](0001193125-25-270230|0) **Interpretation:** The filing record supports that they entered 2026 with a recently strengthened balance sheet (as of the last 10‑Q) and explicit runway guidance (≥12 months). That helps, but Phase 3 AD (two registrational trials) is typically expensive—so I would still treat **future dilution/partnering** as a central watchlist risk item. (This is consistent with their own risk disclosures about capital requirements.) ["substantial future capital requirements"](0000950170-25-039389|0) --- ## 7) So—does the 36‑week “durability” move NKTR up a biotech watchlist? ### My watchlist call (filings‑grounded) **Yes—move it up, but “to the top of the monitoring stack,” not straight to a conviction core holding,** because the filing meaningfully strengthens the *case that the drug can maintain and even deepen responses with less frequent dosing* through 52 weeks, and management is positioning this as a bridge to Phase 3. ["sustained disease control"](0001193125-26-043755|0) ["meaningful proportion of patients achieved new"](0001193125-26-043755|0) ["supports advancement to pivotal Phase 3 program"](0001193125-26-043755|1) ### Why I’m not calling it “full durability de‑risked” yet Because “durability” in biotech often means **off‑treatment durability/remission**, and the company’s own deck shows that the **off‑treatment follow‑up** readout is a later event (Q1 2027). ["1-Year Follow-up (Off Treatment) Data Q1 2027"](0001193125-26-043755|2) --- ## 8) Practical watchlist checklist: what I’d want to see next (all tied to disclosed roadmap) 1) **Phase 3 initiation in Q2 2026** (confirm start, sites/enrollment pace, design specifics). ["plans to start the Phase 3 trials in the second quarter of 2026"](0001193125-26-043755|0) 2) Confirmation that the **co‑primary endpoints (EASI‑75 + IGA‑related endpoint)** and the proposed maintenance regimens remain intact as trials launch. ["co-primary endpoints of EASI-75"](0001193125-26-043755|0) ["IGA-related endpoint"](0001193125-26-043755|0) 3) Any updated disclosure on **target population** (bio‑naïve vs bio‑experienced mix) because that can affect response rates and commercial positioning. ["expected to include patients who have not received prior biologics"](0001193125-26-043755|0) 4) Financing commentary as Phase 3 ramps (the company discloses capital dependence risk and lack of committed capital). ["We have no credit facility"](0001193125-25-270230|0) ["substantial future capital requirements"](0000950170-25-039389|0) --- If you want, I can also extract (and cite) the **exact “Risk Factors” language** from the 2024 10‑K that is most relevant to rezpegaldesleukin concentration risk, Phase 3 failure risk, and funding/dilution risk—and then map those directly to the Phase 3 AD plan described in the Feb. 10, 2026 8‑K. ["we are highly dependent on the success of rezpegaldesleukin"](0000950170-25-039389|0)